We are live on ! Find out more
ITCI

Intra-Cellular Therapies Inc.
ITCI

Delisted

ITCI was delisted on the 1st of April, 2025.

Back to rankings

127 hedge funds and large institutions have $469M invested in Intra-Cellular Therapies Inc. in 2019 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 52 increasing their positions, 28 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

873% more call options, than puts

Call options by funds: $42.6M | Put options by funds: $4.38M

86% more repeat investments, than reductions

Existing positions increased: 52 | Existing positions reduced: 28

12% more capital invested

Capital invested by funds: $418M → $469M (+$51.5M)

0% more funds holding

Funds holding: 127 → 127 (0)

0% more first-time investments, than exits

New positions opened: 13 | Existing positions closed: 13

Holders
127
Holders Change
–
Holders Change %
0%
% of All Funds
2.75%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
13
Increased
52
Reduced
28
Closed
13
Calls
$42.6M
Puts
$4.38M
Net Calls
+$38.2M
Net Calls Change
+$666K

Top Buyers

Rank Fund Capital Flow
1
TA
Teachers Advisors
New York
+$4.89M
2
WA
Wasatch Advisors
Utah
+$4.82M
3
RPAM
Rhenman & Partners Asset Management
Sweden
+$3.7M
4
Vanguard Group
Vanguard Group
Pennsylvania
+$3.61M
5
Schroder Investment Management Group
Schroder Investment Management Group
United Kingdom
+$2.52M

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$12.2M
2
Point72 Asset Management
Point72 Asset Management
Connecticut
-$3.84M
3
FCM
Farallon Capital Management
California
-$2.85M
4
Millennium Management
Millennium Management
New York
-$2.72M
5
Bank of America
Bank of America
North Carolina
-$2.04M
Name Holding Trade Value Shares
Change 		Change in
Stake
LWANC
126
Laurel Wealth Advisors (North Carolina)
North Carolina
$2K – – –
Point72 Asset Management
127
Point72 Asset Management
Connecticut
– -$3.84M -300,352 Closed
FCM
128
Farallon Capital Management
California
– -$2.85M -250,000 Closed
PAM
129
Premier Asset Management
Illinois
– -$721K -63,304 Closed
HI
130
HBK Investments
Texas
– -$610K -53,534 Closed
BG
131
Bellevue Group
Switzerland
– -$599K -52,600 Closed
Los Angeles Capital Management
132
Los Angeles Capital Management
California
– -$581K -51,030 Closed
First Trust Advisors
133
First Trust Advisors
Illinois
– -$274K -24,087 Closed
AQR Capital Management
134
AQR Capital Management
Connecticut
– -$226K -19,837 Closed
Group One Trading
135
Group One Trading
Illinois
– -$250K -19,561 Closed
GCP
136
GSA Capital Partners
United Kingdom
– -$142K -12,449 Closed
PA
137
Profund Advisors
Maryland
– -$138K -12,084 Closed
QT
138
Quantbot Technologies
New York
– -$7K -677 Closed
PCP
139
Proficio Capital Partners
Massachusetts
– +$371 +29 New
2 3 4 5
6

ITCI Hedge Fund Activity: Q1 2019 in Review

127 of the 4,620 institutional investors tracked by Wall St. Rank reported a position in Intra-Cellular Therapies Inc. (ITCI) for Q1 2019, worth a combined $469M — up 12% from $418M a quarter earlier.

Fund positioning in ITCI was balanced in Q1 2019: 13 funds opened new positions, 13 closed out, 52 added to existing stakes and 28 trimmed.

The largest buyer was Teachers Advisors, adding an estimated $4.89M. The largest seller was Citadel Advisors, cutting an estimated $12.2M.

  • 127 institutional investors held Intra-Cellular Therapies Inc. (ITCI) as of Q1 2019, unchanged from Q4 2018.
  • Funds reported $469M of Intra-Cellular Therapies Inc. stock for Q1 2019, up 12% quarter-over-quarter.
  • 13 funds opened new Intra-Cellular Therapies Inc. positions in Q1 2019 and 13 closed out, a net change of 0 holders.
  • The largest Intra-Cellular Therapies Inc. buyer in Q1 2019 was Teachers Advisors, an estimated $4.89M added.
  • The largest Intra-Cellular Therapies Inc. seller in Q1 2019 was Citadel Advisors, an estimated $12.2M sold.

Based on aggregated 13F filings for Q1 2019.